Skip to content
Screener

Bicara Therapeutics BCAX Q3 2025 earnings

Reported November 10, 2025 · Before market open

EPS-$0.67Miss by $0.12
EPS estimate-$0.55

Next report

Aug 11, 2026 (Tomorrow)
EPS estimate-$0.82

Financials

Q3 2025

Income statement

See full
Operating income-$40.7M-97.2%
Net income-$36.3M-108%
EPS (diluted)-$0.67+58.1%

Balance sheet

See full
Cash & equivalents$171.7M-67.0%
Total debt$2.0M+344%
Total equity$402.8M-21.0%
Total assets$424.7M-19.0%

Cash flow

See full
Operating cash flow-$29.2M-69.8%
CapEx$42.0K+425%
Free cash flow-$29.3M-70.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$861.55M—
Enterprise value$691.85M—

Returns & leverage

See full
Return on equity-26.6%—
Debt / equity0×0.0×
Current ratio14.1×-21.9×

FAQ

When did Bicara Therapeutics report Q3 2025 earnings?
Bicara Therapeutics (BCAX) reported Q3 2025 earnings on November 10, 2025 before market open.
What were Bicara Therapeutics's Q3 2025 revenue and EPS?
Bicara Therapeutics reported eps of $-0.67 for Q3 2025.
Did Bicara Therapeutics beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.55 by $0.12.
How did Bicara Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 58.1% from $-1.60.
Where can I find Bicara Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0002023658-25-000107) and the 10-Q periodic report (0002023658-25-000109) directly on SEC EDGAR. The filing index links above go to sec.gov.